What is a stock summary page? Click here for an overview.
Business Description
D&D Pharmatech Inc
ISIN : KR7347850000
Compare
Compare
Traded in other countries / regions
347850.Korea IPO Date
2024-05-02Description
D&D Pharmatech Inc is a company that comprises of experts in the field of bio-new drug research and development and technology commercialization, including basic scientists in the pharmaceutical biofield, manufacturing quality control (CMC) experts, and clinical development and technology transfer experts. Other business areas include the development of positron emission tomography (PET) imaging biomarkers conducted by Precision Molecular Inc. a 100% subsidiary, and single-cell sequencing related to degenerative brain diseases conducted by Valted Seq, Inc. The company utilizes drug delivery technologies such as PEGylation technology, which helps extend the administration interval using PEG and various chemicals, and platform technology that converts injectable drugs into oral preparations.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.07 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.14 | |||||
| Debt-to-EBITDA | -0.48 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 8.67 | |||||
| Beneish M-Score | 3.24 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 86.5 | |||||
| 3-Year EBITDA Growth Rate | 31.8 | |||||
| 3-Year EPS without NRI Growth Rate | 40.2 | |||||
| 3-Year FCF Growth Rate | 31.8 | |||||
| 3-Year Book Growth Rate | -26.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 93.36 | |||||
| 9-Day RSI | 84.44 | |||||
| 14-Day RSI | 76.34 | |||||
| 3-1 Month Momentum % | -8.11 | |||||
| 6-1 Month Momentum % | 17.78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.58 | |||||
| Quick Ratio | 3.58 | |||||
| Cash Ratio | 2.7 | |||||
| Days Sales Outstanding | 39.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.3 | |||||
| Shareholder Yield % | -6.18 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -212.6 | |||||
| Net Margin % | -248.85 | |||||
| FCF Margin % | -238.63 | |||||
| ROE % | -35.97 | |||||
| ROA % | -23.9 | |||||
| ROIC % | -28.87 | |||||
| 3-Year ROIIC % | -29.05 | |||||
| ROC (Joel Greenblatt) % | -347.89 | |||||
| ROCE % | -27.6 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 74.53 | |||||
| PB Ratio | 9.99 | |||||
| Price-to-Tangible-Book | 19.69 | |||||
| EV-to-EBIT | -28.19 | |||||
| EV-to-EBITDA | -33.6 | |||||
| EV-to-Revenue | 72.92 | |||||
| EV-to-FCF | -27.24 | |||||
| Price-to-Net-Current-Asset-Value | 56.41 | |||||
| Price-to-Net-Cash | 266.51 | |||||
| Earnings Yield (Greenblatt) % | -3.55 | |||||
| FCF Yield % | -3.18 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
D&D Pharmatech Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 9,311.739 | ||
| EPS (TTM) (â‚©) | -2228 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 76.34 | ||
| 14-Day ATR (â‚©) | 3805.751462 | ||
| 20-Day SMA (â‚©) | 50805 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (â‚©) | 25100 - 67100 | ||
| Shares Outstanding (Mil) | 10.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
D&D Pharmatech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
D&D Pharmatech Inc Stock Events
| Event | Date | Price (â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
D&D Pharmatech Inc Frequently Asked Questions
What is D&D Pharmatech Inc(XKRX:347850)'s stock price today?
The current price of XKRX:347850 is â‚©66400.00. The 52 week high of XKRX:347850 is â‚©67100.00 and 52 week low is â‚©25100.00.
When is next earnings date of D&D Pharmatech Inc(XKRX:347850)?
The next earnings date of D&D Pharmatech Inc(XKRX:347850) is .
Does D&D Pharmatech Inc(XKRX:347850) pay dividends? If so, how much?
D&D Pharmatech Inc(XKRX:347850) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers